Randomized Study to Compare the Bioavailability of Two Fluticasone Propionate 0.005% Topical Ointments
Completed
- Conditions
- Healthy
- Interventions
- Registration Number
- NCT00803218
- Lead Sponsor
- Padagis LLC
- Brief Summary
The purpose of this study was to compare the relative vasoconstrictive effects of test and reference topical Fluticasone Propionate 0.005% Ointments in healthy, female subjects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 56
Inclusion Criteria
- Non-tobacco using female subjects, 18 to 50 years of age
- Demonstrated blanching response to Reference Drug
- Weight within +/- 20% from normal for height and weight for body frame
- Good health as determined by lack of clinically significant abnormalities in medical history and clinical assessment, as judged by the Investigator
- Signed and dated informed consent form which meets all criteria of current FDA regulations
Exclusion Criteria
- History of allergy to systemic or topical corticosteroids
- Presence of any skin condition or coloration that would interfere with the placement of test sites or the response or assessment of skin blanching
- Presence of medical condition requiring regular treatment with prescription drugs
- Drug or alcohol addiction requiring treatment in the past 12 months prior to dosing
- Use of any tobacco products in the 30 days prior to study dosing
- Use of any dermatological drug therapy on the flexor surface of the forearms within 30 days of dosing
- Receipt of any drugs as part of a research study within 30 days prior to study dosing
- Pregnant or lactating
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Cohort Group 1 Fluticasone Propionate 0.005% Ointment-Reference Product Subjects number 1 to 26 Cohort Group 2 Fluticasone Propionate 0.005% Ointment-Test product Subjects number 27 to 56 Cohort Group 1 Fluticasone Propionate 0.005% Ointment-Test product Subjects number 1 to 26 Cohort Group 2 Fluticasone Propionate 0.005% Ointment-Reference Product Subjects number 27 to 56
- Primary Outcome Measures
Name Time Method Vasoconstriction will be measured by the degree of skin blanching observed after treatment removal using a ChromaMeter Over the course of one day
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of Fluticasone Propionate in vasoconstriction for dermatological use?
How does Fluticasone Propionate 0.005% compare to other corticosteroids in treating inflammatory skin conditions?
What biomarkers correlate with corticosteroid response in healthy subjects during bioavailability studies?
What adverse events are associated with Fluticasone Propionate 0.005% ointment in clinical trials?
Are there combination therapies involving Fluticasone Propionate for enhanced anti-inflammatory efficacy in dermatology?